Our Story

The constant commitment of resources and talent in research, winning strategic choices, the quality of execution and the excellence of our specialty solutions qualify us as one of the most important players in diagnostics worldwide.

With a distinctive managerial character and a vision capable of designing future markets and opportunities in the present, we strategically interpret the evolution of the diagnostic world, remaining faithful to our mission as “Diagnostic Specialists.”

The focus on immunodiagnostics has characterized the company since its origins, but in 2000 a business strategy was developed to raise the company's profile in comparison with the major players in the market. Over a decade, from 2000 to 2010, we focused on specialty and niche products where innovation was key.
This journey was taken in parallel with a significant technological step: in the immunodiagnostics market, modern CLIA technology replaces the older RIA and ELISA.
In this context, DiaSorin acquired the rights to use the LIAISON^® platform, which can read the extensive test menu developed over the years.
Within a decade, we became able to offer the widest CLIA specialty test menu on the market, on fully automated platforms.

The strategic choices made over the previous decade ensured us constant and continuous growth in various areas: we improved our range of tests and production technologies, acquired new types of customers, entered new market segments and strengthened our global commercial presence.
With such a dynamic and specialized profile, we have become a strategic partner for some of the major players in diagnostics worldwide, such as Roche, Beckman Coulter, Meridian Bioscience and QIAGEN. In particular, we entered into a partnership with the latter to develop an innovative solution to screen for latent tuberculosis, one of the most common infectious diseases in the world.
With the acquisition of the US company Focus Diagnostics, now DiaSorin Molecular, we entered the molecular diagnostics sector, a crucial step in light of the 2020 events relating to the pandemic.

The COVID-19 pandemic, which had a major impact on our business in 2020, resulted in significant changes in the world of diagnostics. It let to a strategic reflection on our potential for growth, towards new markets and new types of customers.
First, COVID accelerated the process of the decentralization of diagnostics, highlighting the need to provide patients with diagnostic results increasingly rapidly, by means of simple and cost-effective solutions.
With this in mind, we signed an exclusive license agreement with the British company TTP for the creation of a Point-of-Care (POC) molecular solution, i.e. in close proximity to the patient, on which to use our diagnostic solutions.
In addition, with the acquisition of Luminex, we expanded our offer in the field of molecular diagnostics, equipping it with multiplex technology (with the ability to analyze, in a single diagnostic cycle, multiple parameters starting from a single biological sample) and enter the Life Sciences sector, an area that is laying the foundations for major new collaborations and business opportunities.